Frederick, MD, United States of America

Johanny Kugelman-Tonos


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Inventor Johanny Kugelman-Tonos

Introduction

Johanny Kugelman-Tonos is a notable inventor based in Frederick, MD, known for his significant contributions in the field of pharmaceutical compositions. With two patents to his name, his work has advanced the understanding and treatment of conditions related to androgen receptor function.

Latest Patents

His latest patents include innovative pharmaceutical compositions that inhibit FKBP52-mediated regulation of androgen receptor function. These compositions, referred to as FKBP52 Targeting Agents (FTAs), are designed to bind to a specific interaction surface on the androgen receptor hormone binding domain. By doing so, they effectively inhibit FKBP52 from interacting functionally with the androgen receptor, opening new avenues for treatment and screening methods in this critical area of research.

Career Highlights

Kugelman-Tonos has made significant strides in his career by collaborating with reputable organizations such as the United States Department of Health and Human Services and the University of Texas System. His work with these esteemed institutions has facilitated breakthroughs in the development of new therapeutic approaches, enhancing the landscape of pharmaceutical research.

Collaborations

Throughout his career, he has had the privilege of working alongside esteemed colleagues such as Leonard M Neckers and Marc Cox. These collaborations have enriched his research and contributed to the successful outcomes of his patented innovations.

Conclusion

Johanny Kugelman-Tonos continues to impact the field of pharmaceuticals through his inventive work and collaborations. His dedication to enhancing medical treatments through innovation exemplifies the spirit of modern invention and paves the way for future advancements in androgen receptor research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…